Pre-made Tarextumab benchmark antibody ( Whole mAb, anti-NOTCH2&3 therapeutic antibody, Anti-AGS2/HJCYS/hN2;CADASIL/CADASIL1/CASIL/IMF2/LMNS Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Tarextumab biosimilar, Whole mAb, Anti-NOTCH2&3 Antibody: Anti-AGS2/HJCYS/hN2;CADASIL/CADASIL1/CASIL/IMF2/LMNS therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Tarextumab (formerly OMP-59R5) is a fully human monoclonal antibody targeting the Notch 2/3 receptors. It is being tested as a possible treatment for cancer. In January 2015, the US FDA granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and lung cancer. Two early stage clinical trials have reported encouraging results.
| Products Name (INN Index) | Pre-Made Tarextumab biosimilar, Whole mAb, Anti-NOTCH2&3 Antibody: Anti-AGS2/HJCYS/hN2;CADASIL/CADASIL1/CASIL/IMF2/LMNS therapeutic antibody |
|---|---|
| INN Name | Tarextumab |
| Target | NOTCH2&3 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2013 |
| Year Recommended | 2014 |
| Companies | OncoMed Pharmaceuticals |
| Conditions Approved | NA |
| Conditions Active | Pancreatic cancer,Small cell lung cancer |
| Conditions Discontinued | Solid tumours |
| Development Tech | MorphoSys HuCAL Phage Display;XmAb Engineering Technology |
| Previous Name | NA |
| Gm Offical Target Name | NOTCH2&3 |
| Package |
